Presto Products Company: Paper and Packaging - Company Profile and SWOT Analysis

Summary

"Presto Products Company: Paper and Packaging - Company Profile and SWOT Analysis" contains in depth information and data about the company and its operations. The profile contains a company overview, key facts, major products and services, SWOT analysis, business description, company history, recent developments, key employees as well as company locations and subsidiaries.

Key Findings

This report is a crucial resource for industry executives and anyone looking to access key information about "Presto Products Company"

The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. Canadean strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report.

Synopsis

- Examines and identifies key information and issues about "Presto Products Company" for business intelligence requirements.

- Studies and presents the companys strengths, weaknesses, opportunities (growth potential) and threats (competition). Strategic and operational business information is objectively reported.

- The profile also contains information on business operations, company history, major products and services, key employees, and locations and subsidiaries.

Browse Full Report@ http://www.jsbmarketresearch.com/paper-packaging/r-presto-products-company-paper-and-packaging-company-profile-and-swot-analysis-174655


Reasons To Buy

- Quickly enhance your understanding of "Presto Products Company"

- Gain insight into the marketplace and a better understanding of internal and external factors which could impact the industry.

- Increase business/sales activities by understanding your competitors businesses better.

- Recognize potential partnerships and suppliers.

Key Highlights

Presto Products Company (Presto Products) is a plastic packaging products manufacturer based in the US. It principally offers both flexible and rigid plastic products such as sealable wrap, fresh-lock zippers, reusable storage containers, waste bags, storage bags and wrap, disposable containers and specialty films. The company is involved in providing innovative and eco-friendly soil stabilization and storm water solutions. Presto Products operates through manufacturing facilities across the US. Formerly known as Interim Plastic Corporation, the company operates as a part of Reynolds Group Holdings Limited. Presto Products is headquartered in Appleton, Wisconsin, the US.

For More Related Market Research Reports click here:

Flexible Plastic Packaging Market in the APAC Region 2015-2019

Placon Corporation: Paper and Packaging - Company Profile and SWOT Analysis

Paper and Packaging Market Research

Holiday Stationstores, Inc.: Retailing - Company Profile and SWOT Analysis

Summary

" "Holiday Stationstores, Inc.: Retailing - Company Profile and SWOT Analysis" contains in depth information and data about the company and its operations. The profile contains a company overview, key facts, major products and services, SWOT analysis, business description, company history, recent developments, key employees as well as company locations and subsidiaries.

Key Findings

This report is a crucial resource for industry executives and anyone looking to access key information about " Holiday Stationstores, Inc. "

The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. Canadean strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report.

Synopsis

- Examines and identifies key information and issues about "Holiday Stationstores, Inc." for business intelligence requirements.

- Studies and presents the companys strengths, weaknesses, opportunities (growth potential) and threats (competition). Strategic and operational business information is objectively reported.

- The profile also contains information on business operations, company history, major products and services, key employees, and locations and subsidiaries.

Browse Full Report@ http://www.jsbmarketresearch.com/retail/r-holiday-stationstores-inc-retailing-company-profile-and-swot-analysis-174657

Reasons To Buy

- Quickly enhance your understanding of "Holiday Stationstores, Inc."

- Gain insight into the marketplace and a better understanding of internal and external factors which could impact the industry.

- Increase business/sales activities by understanding your competitors businesses better.

- Recognize potential partnerships and suppliers.

Key Highlights

Holiday Stationstores, Inc. (Holiday Stationstores) is a convenience store chain operator based in the US. The company retails a wide range of food and non-food merchandise including gasoline and fuels, fountain beverages, bakery items, snacks, sandwiches, salads, rollers, pizzas, and soups. It also provides car wash services under the brand Wash Pass. The company also offers Smart Saving credit cards using which customers may save five cents per gallon on the gasoline purchased. It operates through the company owned stores across the US. It was formerly known as Holiday Companies, Inc. Holiday Stationstores is headquartered in Bloomington, Minnesota, the US.


For More Related Market Research Reports click here:

Cumberland Farms, Inc.: Retailing - Company Profile and SWOT Analysis

Pathmark Stores, Inc.: Retailing - Company Profile and SWOT Analysis

Retail Market Research

Nicotine Addiction - Pipeline Review, H1 2015

Nicotine Addiction - Pipeline Review, H1 2015 , provides an overview of the Nicotine Addictions therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Nicotine Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nicotine Addiction and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Nicotine Addiction

- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in the therapeutics development for Nicotine Addiction and enlists all their major and minor projects

- The report summarizes all the dormant and discontinued pipeline projects

- A review of the Nicotine Addiction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- A detailed assessment of monotherapy and combination therapy pipeline projects

- Coverage of the Nicotine Addiction pipeline on the basis of target, MoA, route of administration and molecule type

- Latest news and deals relating related to pipeline products

Browse Full Report@ http://www.jsbmarketresearch.com/healthcare-medical/r-nicotine-addiction-pipeline-review-h1-2015-172978  

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop strategic initiatives by understanding the focus areas of leading companies

- Identify and understand important and diverse types of therapeutics under development for Nicotine Addiction

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Devise corrective measures for pipeline projects by understanding Nicotine Addiction pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope


- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

For More Related Market Research Reports click here:

• Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline Insights, 2015

• Clostridium Botulinum Infections-Pipeline Insights, 2015

• Healthcare and Medical Market Research

Bioinformatics Market by Sector (Molecular Medicine, Agriculture, Forensic, Animal, Research & Gene Therapy), Segment (Sequencing Platforms, Knowledge Management & Data Analysis) & Application (Genomics, Proteomics & Metabolomics) - Global Forecast to 2020

Developing Asian countries such as China and India are lucrative markets for bioinformatics, owing to an increasing number of contract research organizations (CROs), rise in public and private sector investment, and growing industry -academia partnerships.

The report segments the global bioinformatics market by sectors, products and services, application and geography. Knowledge management tools accounted for the largest share of the global bioinformatics market, by product and services in 2014. However, Bioinformatics platforms are expected to grow at the highest CAGR during the forecast period.
 Medical biotechnology accounted the largest share of bioinformatics market, by sector. This large share is attributed to increasing use of bioinformatics in drug discovery and development process for the faster development of new safe and effective drugs at a reduced cost.

On the basis of applications, the bioinformatics market is segmented into genomics, chemoinformatics & drug design, proteomics, transcriptomics, metabolomics and molecular phylogenetics. Genomics is expected to be the fastest growing segment in the bioinformatics application market in the next five years. Browse Full Report@ http://www.jsbmarketresearch.com/technology/r-bioinformatics-market-by-sector-segment-application-global-forecast-68984 

From an insight perspective, this research report focuses on qualitative data, market size, and growth of various segments and subsegments, competitive landscape, and company profiles. The qualitative data covers various levels of industry analysis such as market dynamics (drivers, restraints, opportunities, and threats), winning imperatives, and burning issues. The report also offers market sizes and data on the growth of various segments in the industry.

 It focuses on emerging and high-growth segments, high-growth regions, and initiatives of governments. The competitive landscape covers growth strategies adopted by industry players in the last three years. The company profiles comprise basic views on key players in the bioinformatics market and the product portfolios, developments, and strategies adopted by market players to maintain and increase their market shares in the near future.


 The above-mentioned market research data, current market size, and forecast of future trends will help key players and new entrants to make the necessary decisions regarding product offerings, geographical focus, change in approach, R&D investments for innovations in products and technologies, and levels of output in order to remain successful.

For More Related Market Research Reports click here:

IT Industry Business Confidence Report H1 2015

ICT investment trends in Germany : Enterprise ICT spending patterns through to the end of 2016

Technology Market Research

The Greater China Notebook PC Industry, 1Q 2015

This research report presents shipment volume and value forecast and recent quarter review of the Greater China notebook PC industry. The report includes shipment volume and value, ASP, manufacturer volume ranking, shipment by assembly level, shipment by price point, and product mix analysis.

The content of this report is based on primary data obtained through interviews with notebook PC makers. The report finds that the Greater China notebook PC industrys shipment volume in the fourth quarter of 2014 topped around 37.6 million units, down 1.0% sequentially and 6% year-on-year. In anticipation of the peak seasonal demand in Europe and North America toward year-end, notebook PCs were shipped in advance to those regional markets in the third quarter of 2014.

Hence, the industrys shipment volume declined in the fourth quarter of 2014 as the inventory level at distribution-end remained high and PC branded vendors were more conservative when placing orders. In the first quarter of 2015, the European and US markets are in the inventory clearance phase following the end of seasonal sales period.

Coupled with the depreciation of Taiwanese dollars, Taiwanese PC brands tend to be more cautious about their overseas inventory management. As a result, it is predicted that the industry will see over 10% sequential decline in the first quarter of 2015.

Browse Full Report@ http://www.jsbmarketresearch.com/telecommunications/r-the-greater-china-notebook-pc-industry-69622

Table of Contents

Greater China Notebook PC Shipment Volume, 1Q 2013 - 4Q 2015
Greater China Notebook PC Shipment Value and ASP, 1Q 2013 - 2Q 2015
Greater China Notebook PC Manufacturer Volume Ranking, 1Q 2013 - 4Q 2014
Greater China Notebook PC Shipment Volume by Maker, 1Q 2013 - 4Q 2014
Greater China Notebook PC Shipment Share by Maker, 1Q 2013 - 4Q 2014
Greater China Notebook PC Shipment Volume by Assembly Level, 1Q 2013 - 4Q 2014
Greater China Notebook PC Shipment Share by Assembly Level, 1Q 2013 - 4Q 2014
Greater China Notebook PC Shipment Volume by Screen Size, 1Q 2013 - 4Q 2014
Greater China Notebook PC Shipment Share by Screen Size, 1Q 2013 - 4Q 2014
Greater China Notebook PC Shipment Volume by Computing Platform Types, 1Q 2013 - 4Q 2014
Greater China Notebook PC Shipment Share by Computing Platform Type, 1Q 2013 - 4Q 2014
Greater China Notebook PC Shipment Volume by Price Point, 1Q 2013 - 4Q 2014
Greater China Notebook PC Shipment Share by Price Point, 1Q 2013 - 4Q 2014
Greater China Notebook PC Shipment Volume by Production Location, 1Q 2013 - 4Q 2014
Greater China Notebook PC Shipment Share by Production Location, 1Q 2013 - 4Q 2014
Greater China Notebook PC Shipment Volume by Shipment Destination, 1Q 2013 - 4Q 2014
Greater China Notebook PC Shipment Share by Shipment Destination, 1Q 2013 - 4Q 2014
Greater China Notebook PC Shipment Volume by Business Type, 1Q 2013 - 4Q 2014
Greater China Notebook PC Shipment Share by Business Type, 1Q 2013 - 4Q 2014
Greater China Notebook PC Shipment Volume by Customer, 1Q 2013 - 4Q 2014
Greater China Notebook PC Shipment Share by Customer, 1Q 2013 - 4Q 2014
Intelligence Insight
Research Scope Definitions

For More Related Market Research Reports click here:

The Taiwanese Tablet Industry, 1Q 2015

Chinese Smartphone Market Development, 1Q 2015

Telecommunications market research

Sleep Apnea Devices Market by Segments (Sleep Apnea Therapeutic Devices, Sleep Apnea Diagnostic Devices) - Global Forecast to 2019

The global sleep apnea devices market is expected to grow at a CAGR of 16.6% during the forecast period of 2014 to 2019. North America is the largest market in the global sleep apnea devices market, with a market share of 51.8% as of 2013, followed by Europe and Asia. The largest share of the North American segment is associated with various driving forces, such as the increasing patient pool of sleep apnea in this region, increasing awareness level among patients and caregivers, and the availability of technologically advanced diagnostic and therapeutic devices. It is estimated that approximately 4% of men and 2% of women suffer from Obstructive Sleep Apnea (OSA) globally. Also, the rising prevalence of comorbidities (such as drug-resistant hypertension, congestive heart failure, Type 2 diabetes, and stroke, among others) ensures that the global sleep apnea patient pool will grow in the coming years. However, the inadequate reimbursement coverage and patient compliance are perceived to hinder the growth of this market during the forecast period, 2014 to 2019.

In this report, the global sleep apnea devices market is broadly classified on the basis of segments, namely sleep apnea therapeutic devices and sleep apnea diagnostic devices. The sleep apnea therapeutic devices is further segmented based on types, into home sleep testing/portable monitoring, sleep labs, respiratory polygraphs, two-channel screening devices, single channel screening devices, and actigraphy systems. Similarly, the sleep apnea therapeutic devices market is segmented based on types, into Positive Airway Pressure (PAP) devices, masks, adaptive servo-ventilation, airway clearance systems, oxygen devices, and oral appliances. PAP devices segment is the highest contributor in the therapeutic devices market.

Further, the global sleep apnea devices market is segmented based on the geographies into North America, Europe, Asia, and the Rest of the World (RoW). The North American segment dominated the global sleep apnea devices market in 2013, with a share of 51.8%. The major factors contributing to its dominance are the increasing prevalence of sleep apnea, rising awareness among patients and caregivers about sleep apnea, and the rising popularity of oral appliances, among others. According to the American Academy of Sleep Medicine, the number of accredited sleep labs that test for sleep disorder has quadrupled in the past decade, indicative of the increasing awareness levels in this region about sleep apnea. Europe is the second-largest market for sleep apnea devices, mainly due to the increasing usage of therapeutic devices, growing prevalence of cardiology disorders, increasing prevalence of comorbidities, and presence of well-equipped sleep laboratories. Asia is estimated to be the fastest-growing market in the sleep apnea devices industry as it is projected to grow at a CAGR of 17.7% during the forecast period of 2014 to 2019.

The report has profiled the leading players of this market, along with the developments (New product launches, partnerships, agreements, collaborations, and joint ventures) done by the companies over the past few years and strategies adopted by them to sustain and strengthen their positions in the global sleep apnea devices market. Philips Respironics, a subsidiary of Philips Healthcare (Netherlands); ResMed (U.S.); Compumedics Limited (Australia); Carefusion Corporation (U.S.); Curative Medical, Inc. (U.S.); BMC Medical Co., Ltd. (China); Natus Medical Incorporated (U.S.); Fisher and Paykel Healthcare, Ltd. (New Zealand); DeVilbiss Healthcare (U.S.); Global Medical Holdings, LLC (U.S.); Itamar Medical, Ltd. (U.S.); and Weinmann Medical Devices GmbH & Co. KG (Germany), among others, are some of the key players engaged in this market.

Browse Full Report@ http://www.jsbmarketresearch.com/healthcare-medical/r-sleep-apnea-devices-market-by-segments-global-forecast-167234

Reasons To Buy the Report:

From an insight perspective, this research report has focused on various levels of analysisindustry analysis (industry trends and PEST analysis), market share analysis of top players, supply chain analysis, and company profiles, which together provide the basic views on the competitive landscape; usage patterns; emerging and high-growth segments of the market; high-growth regions and countries, and their respective regulatory policies; government initiatives; and market drivers, restraints, and opportunities.

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help the firms in garnering a greater share in the global market. Firms purchasing the report could use any one or combination of the below mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market share.

The report provides insights on the following pointers:

1. Product Analysis and development: Detailed insights on upcoming technologies, research & development activities, and new product launches in the global sleep apnea devices market; usage pattern/penetration rate (in-depth trend analysis) of products (segment-wise) and purchasing data; and comprehensive coverage of product approvals, patent analysis, pipeline products, and product recalls. 
2. Market Development: Comprehensive information about lucrative emerging markets, across geographies, new distribution channels, new clientele base, and different pricing policies.
3. Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments decisions in the sleep apnea devices market, along with a detailed description of the related and unrelated diversification pertaining to this market.
4. Competitive Assessment: In-depth assessment of market shares and company share analysis of the key players, forecasted till 2019, along with an account of the business strategies and manufacturing capabilities of the leading players.
5. Product/Brand Perception Analysis: A comprehensive study of customers perception and behavior through our inbuilt social connect tool (digital marketing language) checking the virality and tonality of blogs.

For More Related Market Research Reports click here:

• Intraoperative Imaging Market by Type (Intraoperative CT, Intraoperative MRI, Intraoperative Ultrasound) - Global Forecast to 2019

• European Laboratory Information System (LIS) Market by Product (Integrated Laboratory Information System), by Type (Clinical Pathology Laboratory Information System, Anatomic Pathology Laboratory Information System) - Forecast to 2019

• Healthcare and Medical Market Research

Global Biobanking Market 2015-2019

About Biobank

Biobank is a biorepository for the preservation and collection of biological material used for diagnosis, biodiversity studies, and research. Depending on the aims of research, different biobanks store different kinds of samples such as tissues, blood, serum, DNA, and RNA. The human biobanks work by systematic collection of biological samples from patients and other members of the public. Biobanks significantly vary in size such as biobanks held in medical institutions hold relatively modest number of samples compared with a national biobank, which hold a large number of samples. Biobanks are commonly used to support research of most common types of genetic disorders, for developing personalized medicine, for stem cell research, and for maintaining and updating age demographic databases.

TechNavios analysts forecast the Global Biobanking market to grow at a CAGR of 7.07 percent over the period 2014-2019.

Covered in this Report

The Global Biobanking market cn be divided into two segments: Equipment and Consumables. This report covers the present scenario and the growth prospects of the Global Biobanking market for the period 2015-2019.

TechNavios report, Global Biobanking Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

Americas
APAC
EMEA

Key Vendors

Beckman Coulter
Tecan
Thermo Fischer Scientific

Browse Full Report@ http://www.jsbmarketresearch.com/healthcare-medical/r-global-biobanking-market-2015-2019-170326  

Other Prominent Vendors

Askion GmBH
B&C Group
BioBank
BioCryo
BioRep SRL
BioStorage Technologies
Bluechip
Brooks Life Science Systems
Cryo Bio System
CryoXtract
DNA Genotek
Excilone
Fluidx
Indivumed
LVL Technologies
Micronic
Promega
QIAGEN
RURO
Seralab
SOL Group
Tissue Solutions
Trans-Hit Biomarkers
Wildcat Laboratory Solutions

Market Driver

Advances in Technology
For a full, detailed list, view our report

Market Challenge

Public Trust for Biobanking
For a full, detailed list, view our report

Market Trend

Increase in Strategic Collaborations
For a full, detailed list, view our report

Key Questions Answered in this Report

What will the market size be in 2019 and what will the growth rate be?
What are the Key Market Trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?


For More Related Market Research Reports click here:

• Lymphoblastic Lymphoma-Pipeline Insights, 2015

• Cluster Headache Syndrome-Pipeline Insights, 2015

• Healthcare and Medical Market Research

Mid and High Level Precision GPS Market by Type (Differential Grade and Survey Grade), Application (Precision Farming, Mining, Construction, Oil & Gas) and Geography - Global Forecast to 2020

The factors such as ongoing developments to improve the overall GPS infrastructure, technological advancements and GPS augmentation, and availability of more cost-effective GPS solutions are driving the mid and high level precision GPS market. Ongoing developments in the GPS technology are likely to enhance coverage and reliability. It is expected that enhancements in terms of coverage would drive the increased penetration of GPS technology in a wide array of applications.

However, heavy reliance on the availability of satellites and low market acceptance for new technologies are the major restraining factors for this market. The time taken by end-users to adopt new technology is hindering the growth of the precision GPS market.

This report on the mid and high level precision GPS market reviews the latest market trends such as GPS augmentation, Micro-technology for Positioning, Navigation, and Timing (Micro-PNT), and Adaptable Navigation Systems (ANS) that would help estimate the future growth prospects.

Browse Full Report@ http://www.jsbmarketresearch.com/electronics/r-mid-and-high-level-precision-gps-market-by-type-application-171281

The emerging economies are providing a growth opportunity to the small and medium sized companies in the mid and high level precision GPS market. The in-depth geographic analysis in the report provides strategic business intelligence for mid and high level precision GPS sector investments. The study reveals profitable investment strategies for mid and high level precision GPS companies, business executives, product marketing managers, new business investors, and many more in preferred locations.

The report also provides the Porter’s Five Forces analysis for the mid and high level precision GPS market. This analysis highlights the current scenario and provides an insight into the key parameters that directly or indirectly play a role in either the growth or decline of the mid and high level precision GPS market.

The five parameters termed as the five forces determine the intensity of competition and attractiveness of the mid and high level precision GPS market. The competitive landscape section of the report primarily focuses on the key industry players in the mid and high level precision GPS industry, their latest developments, and respective rankings in the said market. In addition to that, the report also comprises the emerging market trends, key growth areas and market size, region wise demand factors, and the key competitors for the said companies.

For More Related Market Research Reports click here:

• China Antitrust Sentence and Its Impact on Qualcomm and the Chinese Industry

• North America IR Detector Market by Technology (MCT, InGaAs, Pyroelectric, Thermopiles, and Microbolometers), by Spectral Range (SWIR, MWIR, and LWIR), by Application, and by Geography - Analysis and Forecast till 2019 

• Electronics Market Research

Biodegradable Stents

This study gives an insight into Global Stents and Biodegradable Stents market. The Bio degradable market research report also provides an overview of the Worldwide Bare Metal Stents and Drug Eluting Stents market size. Market analytics for Biodegradable Stents by Application and by Biodegradable Material is provided in this niche report. The market is divided by Application into Coronary Arterial Stents, Peripheral Arterial Stents and Other; and by Biodegradable Material into Polymer and Metal.Global stents market is analyzed from 2005 -2020, while estimations and predictions for biodegradable stents market are provided from 2015-2020. Key market dynamics are provided for North America, Europe, Asia-Pacific, and Rest of World (RoW). Business profiles of 25 biodegradable stents companies are discussed in the report. Information related to recent product releases, product developments, partnerships, collaborations, and mergers and acquisitions is also covered in the report.

Browse Full Report@ http://www.jsbmarketresearch.com/healthcare-medical/r-biodegradable-stents-68384 

Table of Contents

1. SCOPE AND METHODOLOGY
 2. REPORT SYNOPSIS
 2.1 Introduction
 Types of Stents
 Bare-Metal Stents
 Drug Eluting Stents (DES)
 Everolimus
 Sirolimus
 Biolimus A9
 Pimecrolimus
 Biodegradable Stents
 Raw Materials
 Polymeric Stents
 Degradation of Biodegradable Polymers
 Processing of Biodegradable Polymers
 Role of Biodegradable Polymers
 In Tissue Engineering
 In Controlling Drug Delivery
 Application
 Polymer based Stents
 Igaki-Tamai Stent
 ReZolve Stent
 Everolimus - Eluting Stent
 Metal Stents
 Bioabsorbable Metal based Stents
 Magnesium Stents
 Combination Stents
 Tacrolimus –eluting Cobalt –Chromium Polymer Stent
 Applications of Biodegradable Stents
 2.2 Segmentation
 Exhibit 1. Segmentation of Stents Market by Type and by Application (2005 -2015)
 Exhibit 2. Segmentation of Biodegradable Stents Market by Application and by Biodegradable Material (2015 - 2020)
 2.3 Stents - Global Market Analysis
 Exhibit 3. Stents - Global Value Market Estimations & Predictions (2005 -2015) in US$ Million (Graphical Representation Included)
 2.4 Biodegradable Stents - Global Market Analysis
 Exhibit 4. Biodegradable Stents - Global Value Market Estimations & Predictions (2015 -2020) in US$ Million (Graphical Representation Included)
 Exhibit 5. List of Global Major Companies in Biodegradable Stents Market

For More Related Market Research Reports click here:

Liver Transplantation-Pipeline Insights, 2015

Local Anesthetic Effect-Pipeline Insights, 2015

Healthcare and Medical Market Research

Air Quality Monitoring Equipment Market by Product (Portable, Fixed Gas, Dust & Particulate Monitors), End User (Commercial & Residential, Power, Pharmaceutical, Academia), Component (Physical, Chemical, Biological) - Global Forecast to 2019

This report segment the global air quality monitoring equipment market by end users, products, technology, component, and geographies. The end user segments included in this report are commercial and residential users, government and academia, pharmaceutical industry, power plants, refining, and oil and gas, and other industries.

 The product segments included in this report are indoor air quality monitors and outdoor air quality monitors. Indoor fixed monitors and indoor portable monitors are sub segments of the indoor air quality monitoring equipment segment. AQM stations, dust & particulate monitors, outdoor fixed monitors, and outdoor portable monitors are sub segments of the outdoor air quality monitoring equipment market.
 The geographic segments included in this report are Asia, Europe, North America and Rest of the World (RoW). North America includes Canada, and the U.S.

 The key drivers for this market are increased health concerns and stringent air pollution control by government organizations. Moreover, Increased in air pollution are also expected to drive the market growth.
 A combination of bottom-up and top-down approaches were used to calculate market sizes and growth rates of the global air quality monitoring equipment market and its sub segments. Secondary information was used to identify overall revenue, geographic reach, and product portfolios of market players. Estimates of their air quality monitoring equipment market segment revenues were validated through primary interviews. Primary interviews with key opinion leaders were also used to determine the percentage shares of each subsegment and the relative differences in growth rates.

 The report provides qualitative insights on key market shares, growth rates, and market drivers for all important subsegments. It maps market sizes and growth rates of each subsegment and identifies segments poised to see rapid growth. The report also includes company profiles of market leaders. These company profiles include the financial performances, product portfolios, and developments of each company. The report also provides a competitive landscape of the air quality monitoring equipment market. The competitive landscape covers the growth strategies adopted by industry players over the last three years. It also includes analyses of industry developments like mergers and acquisitions, agreements and partnerships, and new product launches.

Browse Full Report@ http://www.jsbmarketresearch.com/healthcare-medical/r-air-quality-monitoring-equipment-market-by-product-component-global-forecast-170179 

Reasons To Buy the Report:

The report will enable both established firms and new entrants to gauge the pulse of the market and help them make important strategic growth decisions.

 The report provides insights on the following:

• Product Development/Innovation: Product portfolios of top players in the air quality monitoring equipment market. Detailed insights on upcoming technologies, research and development activities, and new product launches in the air quality monitoring equipment market
• Competitive Assessment: In-depth assessment of market shares, strategies, geographic and business segments, and product portfolios of leading players in the air quality monitoring equipment market

 • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the market for various air quality monitoring equipment across geographies
 • Market Diversification: Exhaustive information about new products, recent developments, and investments in the air quality monitoring equipment market.

 For More Related Market Research Reports click here:

Global Business Process Management (BPM) as a Service Market 2015-2019

Recruitment Process Outsourcing (RPO) Market in the APAC Region 2015-2019

Business Services Market Research

GV Gold : Company Profile and SWOT Analysis

Synopsis

 "GV Gold : Company Profile and SWOT Analysis" contains in depth information and data about the company and its operations. The profile contains a company overview, key facts, major products and services, SWOT analysis, business description, company history, key employees as well as company locations and subsidiaries.

Summary

This report is a crucial resource for industry executives and anyone looking to access key information about "GV Gold"

The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. World Market Intelligence strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report.

Scope

Examines and identifies key information and issues about "GV Gold" for business intelligence requirements.

Studies and presents the companys strengths, weaknesses, opportunities (growth potential) and threats (competition). Strategic and operational business information is objectively reported.

The profile also contains information on business operations, company history, major products and services, key employees, and locations and subsidiaries.

Browse Full Report@ http://www.jsbmarketresearch.com/materials/r-gv-gold-company-profile-and-swot-analysis-169608 

Reasons To Buy

Quickly enhance your understanding of "GV Gold"

Gain insight into the marketplace and a better understanding of internal and external factors which could impact the industry.

Increase business/sales activities by understanding your competitors businesses better.
Recognize potential partnerships and suppliers.

Key Highlights

GV Gold (GVG) is a gold mining and exploration company. The company carries out its mining and exploration operations in Irkutsk Region and Sakha (Yakutia) Republic. The companys Irkutsk project includes Golets Vysochaishy deposit, Ugakhan deposit, Ykanskoye deposit, and Babushkin site located in Bodaibo area, Irkutsk Region. It also owns interests in Yakutia project, including Big Kuranakh deposit, Drazhnoye deposit, and Central Part of the Taryn Ore Field located in Sakha (Yakutia) Republic. The partners of the company include Lanta bank CJSC, JSC Mining Production and Financial Company, and IRGIREDMET JSC. The company operates through its representative office in Moscow and through its subsidiaries. GVGs property portfolio includes more than 10 licenses with total area of over 700 square kilometers. GVG is headquartered in Bodaibo, Russian Federation.

For More Related Market Research Reports click here:

• Global High Temperature Insulation (HTI) Materials Market 2015-2019

• Global Mining Taxes and Royalties 2015

• Materials Market Research

Complete 2015-16 Induced Pluripotent Stem Cell (iPSC) Industry Report

Stem cell research and experimentation have been in process for well over five decades, as stem cells have the unique ability to divide and replicate repeatedly. In addition, their “unspecialized” nature allows them to differentiate into a wide variety of specialized cell types. The possibilities arising from these characteristics have resulted in great commercial interest, with potential applications ranging from the use of stem cells in reversal and treatment of disease, to targeted cell therapy, tissue regeneration, pharmacological testing on cell-specific tissues, and more. Conditions such as Huntington’s disease, Parkinson’s disease, and spinal cord injuries are examples of clinical applications in which stem cells could offer benefits in halting or even reversing damage.

Traditionally, scientists have worked with both embryonic and adult stem cells for research tools, as well as for cellular therapy. While the appeal of embryonic cells has been their ability to differentiate into any type of cell, there has been significant ethical, moral, and spiritual controversy surrounding their use. Although some adult stem cells do have differentiation capacity, it is often limited in nature, which results in fewer options for use. Thus, induced pluripotent stem cells represent a promising combination of adult and embryonic stem cell characteristics.

Discovery of Induced Pluripotent Stem Cells

Groundbreaking experimentation in 2006 led to the introduction of induced pluripotent stem cells (iPSCs). These are adult cells which are isolated and then transformed into embryonic-like stem cells through the manipulation of gene expression, as well as other methods. Research and experimentation using mouse cells by Shinya Yamanaka’s lab at Kyoto University in Japan was the first instance in which there was successful generation of iPSCs.[1] In 2007, a series of follow-up experiments was done at Kyoto University in which human adult cells were transformed into iPSC cells. [2] Nearly simultaneously, a research group led by James Thomson at the University of Wisconsin-Madison accomplished the same feat of deriving iPSC lines from human somatic cells.[3]

Continued research and experimentation have resulted in numerous advances over the last few years. For example, several independent research groups have announced that they have derived human cardiomyocytes from iPSCs. These cells could be used in a laboratory context to test drugs that treat arrhythmia and other cardiac conditions, and in a clinical context they could potentially be implanted into patients with heart disorders.

Similar advances will continue to be perfected for use of reprogrammed adult cells in the treatment of other diseases and disorders. Original techniques for iPSC production, such as viral induced transcription processes, are being replaced with newer technologies as private industry joined with the scientific community to develop safer and more efficient methods of iPSC production. As innovation around methods of iPSC production continues, clinical grade production of industrial quantities of iPSCs is now becoming possible due to sustained research and experimentation.

Browse Full Report@ http://www.jsbmarketresearch.com/healthcare-medical/r-complete-2015-16-induced-pluripotent-stem-cell-ipsc-industry-report-124650

Therapeutic Applications of Induced Pluripotent Stem Cells

While there has been continued excitement at the prospect of what such artificially re-manufactured cells could contribute to medical advances, there have also been setbacks along the way. By 2010, there were a number of private companies that were ready to capitalize on the breakthrough technology that iPSCs represent. One such company, Advanced Cell Technology (ACT) in Marlborough, Massachusetts, discovered several problematic issues while conducting experiments for the purpose of applying for U.S. Food and Drug Administration approval to use iPSCs in therapeutic applications. Concerns such as premature cell death, mutation into cancer cells, and low proliferation rates were some of the problems that surfaced.

As a result, ACT (now named “Ocata Therapeutics”) has shifted its induced pluripotent stem cell approach to producing iPSC derived human platelets. One of the benefits of a platelet-based product is that platelets do not contain nuclei, and therefore, cannot divide or carry genetic information. While nothing is completely safe, iPSC derived platelets are likely to be substantially safer than other currently available iPSC therapies, in which uncontrolled proliferation may be a concern. It also shifted to using embryonic stem cells for clinical trial purposes, despite the ethical concerns surrounding this cell type.

Over the next few years, iPSC research advances accelerated exponentially, with perhaps the most momentous milestone being the launch of the first clinical research trial ever involving the transplant of autologous iPSCs into humans (“autologous” meaning the cells are both derived and implanted into the same patient). Previously, all clinical trials using iPSCs involved only the creation of iPSC lines from specific patient populations and subsequent evaluation of these lines for determining whether they could represent a good “model” for a disease of interest within that population.

Therefore, 2013 was the first time in which clinical research involving transplant of iPSCs into humans was initiated, led by Masayo Takahashi of the RIKEN Center for Developmental Biology in Kobe, Japan. Dr. Takahashi and her team are investigating the safety of iPSC-derived cell sheets in patients with wet-type age-related macular degeneration. While the trial was initiated in 2013 and production of iPSCs from patients began at that time, it was not until August of 2014 that the first patient, a Japanese woman, was implanted with retinal tissue generated using iPSCs derived from her own skin cells. A team of three eye specialists, led by Yasuo Kurimoto of the Kobe City Medical Center General Hospital, implanted a 1.3 by 3.0mm sheet of iPSC-derived retinal pigment epithelium cells into the patient’s retina.[4] Preliminary results are indicating positive results for the participants in this iPSC clinical trial.

Interestingly, Ocata Therapeutics (previously ACT) is conducting similar research, but the company has moved away from its initial focus on iPSCs and has instead chosen to focus on human embryonic stem cells (hESCs). It is currently conducting clinical trials using retinal pigmented epithelial cells produced from hESCs for purposes of treating several types of macular degeneration. The company reported positive preliminary results, which were published in the Lancet in October 2014.[5]

Also of great significance, Kyoto University Hospital in Kobe, Japan announced in February of 2015 that it will be opening an iPSC therapy center in 2019, for purposes of conducting clinical studies on iPSC therapies. The announcement has further positioned Japan as the leading nation committed to bringing iPSC therapies to clinic. Officials for Kyoto Hospital said it will open a 30-bed ward to test the efficacy and safety of the therapies on volunteer patients, with the hospital aiming to initiate construction at the site in February of 2016 and complete construction by September 2019.[6]

Current research with iPSCs underway at Kyoto University includes differentiation of iPSCs into dopamine-releasing neurons for transplantation into patients who are afflicted with Parkinson’s disease. University researchers are also working on generating a formulation of platelets that will assist with blood clotting. Dr. Shinya Yamanaka, who is credited with discovering iPSCs in 2006 and who shared the 2012 Nobel Prize in Medicine for the discovery, leads the existing iPSC research center at Kyoto University.

As such, the two founders of iPSC technology (Dr. Shinya Yamanaka and Dr. James Thomson) remain two of the most significant influencers in the iPSC sector. Recall that Dr. Shinya Yamanaka, who will be operating the iPSC therapy center scheduled to open in Japan in 2019, created the first successful generation of iPSCs in 2006,[7] and in 2007, performed follow-up experiments in which his team transformed human adult cells into iPSC cells.[8] Nearly simultaneously, a research group led by James Thomson at the University of Wisconsin-Madison accomplished the same feat of deriving iPSC lines from human somatic cells.[9] James Thomson is both the Founder and current Chief Scientific Officer of Cellular Dynamics International (CDI), a leading supplier of human iPSC lines for purposes that include drug discovery, safety, stem cell banking, cellular safety, and more.

Landmark Events Create Market Opportunities

In 2009 ReproCELL, a company established as a venture company originating from the University of Tokyo and Kyoto University, was the first to make iPSC product commercially available with the launch of human iPSC-derived cardiomyocytes, which it called “ReproCario.”[10] Other stem cell derived cardiomyocytes are now available commercially from Cellular Dynamics International, GE Healthcare, Cellectis, and others.

ReproCELL’s innovation in the area of iPSC commercialization has been driven in part by joint research relationships it established in 2003 with Tokyo University and in 2004 with Kyoto University, the eventual site of iPSC discovery in 2006.[11]. Since 2009, ReproCELL has expanded its line of iPSC reagents and iPSC-derived cell lines to include heart, liver, and nerve cells.

The company primarily sells these products as research tools, although they also have the potential for use in toxicology and drug discovery applications. Currently, ReproCELL offers the following iPSC products: [12]

• Research reagents optimized for human iPSC culture

• Human iPSC-derived cardiomyocytes, which launched in April of 2009 (the first iPSC product to be sold commercially)

•  Human iPSC-derived neurons, launched in October of 2010

• Human iPSC-derived hepatocytes, launched in May of 2012

• Disease model cell generation using human iPS cell technologies

To date, ReproCELL has furthered its dominance in the area of iPSC products through a series of strategic acquisitions, including acquisition of Reinnervate, Stemgent, and BioServe Biotechnologies, all occurring in 2014. [13]

Cellular Dynamics International (CDI) is another major market player in the iPSC sector. Similar to ReproCELL, CDI established its “foothold” on the iPSC industry early, being founded in 2004 by Dr. James Thomson at the University of Wisconsin-Madison, who in 2007 subsequently derived iPSC lines from human somatic cells for the first time ever (although the feat was also accomplished simultaneously by Dr. Shinya Yamanaka’s lab in Japan).[14] CDI currently holds more than 800 patents, which gives it a strong competitive position within the marketplace.

CDI has been promoting adoption of iPSC technology by adapting its methods to fit into standard clinical practice through the creation of individual stem cell lines from a standard blood draw.[15] In a landmark event, the company went public in July 2013 with a public offering that raised $43 million dollars, securing its position as the global leader in producing high-quality human iPSCs and differentiated cells in industrial quantities.

Then, in March of 2013, Cellular Dynamics International (CDI) and the Coriell Institute for Medical Research announced receipt of multi-million dollar grants from the California Institute for Regenerative Medicine (CIRM) for the creation of iPSC lines from 3,000 healthy and diseased donors. CIRM awarded CDI $16 million to create three iPSC lines for each of 3,000 healthy and diseased donors and awarded the Coriell Institute $10 million to set up and biobank the iPSC lines. The result will be thecreation of the world’s largest human iPSC bank, an incredible feat.

Not surprisingly, Cellular Dynamics International has continued its innovation, announcing in February of 2015 that it would be manufacturing cGMP HLA “Superdonor” stem cell lines that will support cellular therapy applications through genetic matching.[16]Currently, CDI has two HLA superdonor cell lines that provide a partial HLA match to approximately 19% of the population within the U.S., and it aims to expand its master stem cell bank by collecting more donor cell lines that will cover 95% of the U.S. population.[17] The HLA superdonor cell lines were manufactured using blood samples, and used to produce pluripotent iPSC lines, giving the cells the capacity to differentiate into nearly any cell within the human body.

CDI also leads the iPSC market in terms of supporting drug development and discovery. For example, CDI’s “MyCell” products are created using custom iPSC reprogramming and differentiation methods, thereby providing biologically relevant human cells from patients with unique disease-associated genotypes and phenotypes.[18] The company’s iCell and MyCell cells can also be adapted to screening platforms and are matched to function with common readout technologies.[19] CDI’s products are also used for high-throughput screening,[20] and have been used as supporting data for Investigational New Drug (IND) applications submitted to the Federal Drug Administration (FDA).[21] While there are other companies participating in this area – including ReproCELL, Cellectis, ArunA Biomedical, and others – competitors are limited and CDI currently leads the way.

The California Institute for Regenerative Medicine (CIRM), an organization tasked with deploying $3 billion dollars in California tax money to support the translation of stem cell research into clinical therapies, has increasingly been favorable toward funding iPSC research projects with a clinical (“translational”) focus. In one example, the Parkinson’s Institute was awarded $6.5 million to support four separate research projects focusing on development of patient-specific iPSCs from individuals with Parkinson’s disease.[22]Within a brief period of time, CIRM awarded $3 million to the Cedar-Sinai Medical Center for derivation of iPSCs from patients with inherited nerve disease and for research into the feasibility of transplanting these cells back into patients after genetic corrections have been applied.[23] $1.3 million was next awarded to Stanford University to allow for creation of cardiomyocytes from iPSCs that can be used to explore causes of cardiovascular disease.[24] Clearly, CIRM’s favorability toward funding iPSC research is gathering momentum.

Taken in aggregate, the iPSC market forces described above are creating incredible enthusiasm and commercial interest in the iPSC sector. Never before has there been such a rare combination of landmark events supporting development of iPSC tools, technologies, and importantly, therapies. Indeed, recent years have seen major advances in clinical research applications, production and differentiation technologies, and biobanking of iPSCs. There have also been major funding awards, large initial public offerings (IPOs), significant patent challenges, and more. For companies and investors competing within the iPSC marketplace, it is critical to understand these major market events and how they are shifting industry dynamics.

Induced Pluripotent Stem Cell Patent Challenges

The patent environment for iPSCs is complicated, and there are a number of restrictions on how the cells can be used for commercial purposes. 2015 has witnessed a historic patent challenge, one that is challenging the way that iPSCs are derived and utilized for commercial purposes. The 2015 patent challenge could rival in importance the infamous Wisconsin Alumni Research Foundation (WARF) dispute that pertained to patents surrounding the derivation of human embryonic stem cells (hESCs). Jeanne Loring of Scripps Research Institute, and two public interest groups, Consumer Watchdog and the Public Patent Foundation, challenged the WARF patents in 2006. To date, the WARF patent dispute has been the most defining patent dispute within the stem cell sector, although it was settled in U.S. courts between 2008 and 2010, [25] appeals have continued through February of 2015.[26]

In 2006, Drs. Yamanaka and Takahashi filed a U.S. patent claiming a method for creating iPSCs titled “Oct3/4, Klf4, c-Myc and Sox2 produce induced pluripotent stem cells,” which was issued as U.S. Patent No. 8,058,065 on November 15, 2011. While there have been other patents issued pertaining to the cellular reprogramming and creation of iPSCs, this patent is the dominant one within the iPSC sector and the most common one that limits commercial development of iPSC products.

Often called the “Yamanaka Patent,” this famous patent is being challenged by a group called “BioGatekeeper.” If the “Yamanaka Patent” challenge is successful, it could spur incredible innovation within the stem cell sector by allowing for lower cost creation of iPSC products, technologies, and therapies. Currently, most companies are forced to pay licensing fees to use the methodology described in the “Yamanaka Patent,” fees which are often prohibitively expensive.

In February of 2015, a long series of appeals to WARF’s embryonic stem cell patents ended with the U.S. Supreme Court decision to not hear appeals to the case being brought by Consumer Watchdog of Santa Monica, California, and Jeanne Loring, head of the stem cell program at Scripps Research Institute.[27] The decision means that WARF will get to keep its patent rights for embryonic stem cells, discovered in 1998 by James Thompson, founder of CDI. Nonetheless, the challengers succeeded in preventing WARF from gaining rights over induced pluripotent stem cells, which would have given WARF nearly impenetrable control over pluripotent stem cells, as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSC) are two of the most versatile stem cell types.[28]

Four Primary Areas of Commercialization

There are currently four major areas of commercialization for induced pluripotent stem cells, as described below:

1) Drug Development & Discovery: iPSCs have the potential to transform drug discovery by providing physiologically relevant cells for compound identification, target validation, compound screening, and tool discovery.

2) Cellular Therapy: iPSCs can be used for cellular therapy applications, including autologous transplantation and potentially gene therapy. The purpose of cellular therapy is to reverse injury or disease.

3) Toxicology Screening: iPSCs can be used for toxicology screening, which is the use of stem cells or their derivatives (tissue-specific cells) to assess the safety of compounds or drugs within living cells.

4) Stem Cell Biobanking: The goal of stem cell biobanking is to create a repository of stem cell specimens, including source tissue from which iPSCs can be derived, differentiated cell types produced from iPSCs, and disease tissues produced from iPSCs. Large-scale stem cell repositories provide researchers with the opportunity to investigate a diverse range of conditions using iPSC derived cells produced from both healthy and diseased donors. Importantly, these repositories can also greatly expand the capacity for global research and collaboration.

Each of these areas will be vital to the future commercialization of iPSCs. At this time, Cellular Dynamics International (CDI) is best positioned to excel in all areas, largely due to its participation in creating the world’s largest ever iPSC bank (funded through a CIRM grant and in partnership with Coriell Institute for Medical Research), and its ability to produce clinical grade iPSCs in industrial quantities. However, there are other industry competitors that could be well-positioned to control one of these market areas, such as ReproCELL’s strong positioning in the iPSC reagent space. Therefore, smaller industry players may choose to specialize and compete in one of these market areas, with the potential for later expansion into other areas.
Rapidly-Evolving Market Opportunities for iPSCs

Since the discovery of iPSCs a large and thriving research product market has grown into existence, largely because the cells are completely non-controversial and can be generated directly from adult cells. Today, the number of iPSC products sold worldwide is increasing with double-digit growth. In addition, 22% of all stem cell researchers now self-report having used iPSCs within a research project. It is clear that iPSCs represent a lucrative product market, but methods for commercializing this cell type are still being explored, as clinical studies investigating iPSCs continue to increase in number.

Currently, nearly all clinical studies involving iPSCs are for the creation and evaluation of iPSC lines from specific patient populations in order to determine if these cell lines could be a good model for a disease of interest in that patient population. (See ClinicalTrials.gov for a current list of these trials or view the “Clinical Trial Trend Analysis” section of this report for a full discussion of findings.) However, the first clinical study involving transplant of iPSCs into humans was initiated in August 2013.

Market Leaders Have Begun to Emerge in All Areas of iPSC Development
Finally, market leaders have begun to emerge in all areas of iPSC development, including:

• Drug Development and Discovery: Cellular Dynamics International (CDI) in Madison, Wisconsin

• Cellular Therapy (Therapeutic Applications of iPSCs): RIKEN Center, in Kobe, Japan, and Kyoto University in Kyoto, Japan

• Stem Cell Biobanking: Cellular Dynamics International (CDI) in Madison, Wisconsin

• iPSC Research Products: ReproCELL in Kanagawa, Japan; Thermo Fisher Scientific in Rockville, MD; STEMCELL Technologies in Vancouver, Canada; and BD Biosciences in San Jose, California

End-User Survey of iPSC Scientists

A distinctive feature of this report is an end-user survey of 273 researchers (131 U.S. / 143 International) that identify as having induced pluripotent stem cells as a research focus. These survey findings reveal iPSC researcher needs, technical preferences, key factors influencing buying decisions, and more. The findings can be used to make effective product development decisions, create targeted marketing messages, and produce higher prospect-to-client conversion rates.

Key Report Findings Include:

Metrics, Timelines, Tables, and Graphs for the iPSC Industry
Trend Rate Data for iPSC Grants, Clinical Trials, and Scientific Publications
Analysis of iPSC Patent Environment, including Key Patents and Patent Trends
Market Segmentation
5-Year Market Size Projections (2015-2019)
Market Size Estimations, by Market Segment
Updates on Crucial iPSC Industry and Technology Trends
Analysis of iPSC Market Leaders, by Market Segment
Geographical Assessment of iPSC Innovation
SWOT Analysis for the iPSC Sector (Strengths, Weaknesses, Opportunities, Threats)
Preferred Species for iPSC Research
Influential Language for Selling to iPSC Scientists
Breakdown of the Marketing Methods, including Exposure and Response Rates
And Much More

Summary of Findings

Induced pluripotent stem cells represent a promising tool for use in the reversal and repair of many previously incurable diseases. The cell type represents one of the most promising advances discovered within the field of stem cell research during the past decade, making this a valuable industry report for both companies and investors to claim in order to optimally position themselves to sell iPSC products. To profit from this lucrative and rapidly expanding market, you need to understand your key strengths relative to the competition, intelligently position your products to fill gaps in the market place, and take advantage of crucial iPSC trends.

Input Sources

The content and statistics contained in this report were compiled using a broad range of sources. These sources include:

Stem Cell Grant Funding Database (NIH database)
Stem Cell Patent Database (USPTO)
Stem Cell Clinical Trial Database (ClinicalTrials.gov) Stem Cell Scientific Publication Database (PubMed)
Stem Cell Product Launch Announcements (Trade Journals, Google News)
Stem Cell Industry Events (Google News, Google Alerts)
Stem Cell Company News (SEC Filings, Investor Publications)
International Surveys (Electronically Distributed End-User Surveys)
And More

Methodologies

BioInformant employs multiple techniques for deriving market research. The following constitute the basis for our Research & Analysis:

• Preliminary Research: Extensive secondary research based on preliminary market evaluations

• Fill-Gap Research: Selectively sampled and focused primary research as a fill-gap strategy

• Historic Analysis – Primary Products: Comprehensive analysis of all data for each primary product market

• Historic Analysis – End-user Markets: Historic analysis of all end-user industries/markets, requiring technology and market evaluations, growth projections, and market size estimation of end-user markets

• Historic Supply Chain/Raw Materials Analysis: Comprehensive analysis of data for each primary market segment

• Data Consolidation: Merging historic end-user market data to yield consolidated primary market data

• Cross Linking: Comparing primary market data (historic) with resulting end-user consolidated market data and calculating the variance in percentages between data sets by year

• Variance Determination: Placing a median figure for each year with a tolerance range equal to twice the variance percentage and recording the resulting numbers

• Projections: Projecting forward end-user markets based upon historic metrics, technology and market trends, and primary research from the marketplace

• Variance Factorization: Consolidation of projected end-user market data to yield derived primary market data. The data is adjusted to the historic variance determinations, as above. The resulting data is verified by confirmatory primary research

• Confirmatory Primary Research: Presenting resulting data from companies or individuals participating as research partners. Variations from derived data are adjusted to reflect primary research based consensus

• Electronically Based End-User Surveys: Distribution of electronically based end-user surveys to a panel of industry representatives working within market segment(s) of interest. Statistical filtering and analysis is performed on collected user-response data

For More Related Market Research Reports click here:

Allergan, Inc. (AGN) - Financial and Strategic SWOT Analysis Review

Ultradent Products, Inc. - Strategic SWOT Analysis Review

Healthcare and Medical Market Research